WELLINGTON, New Zealand — Police raids at the rural Northland home of cannabis advocate Paul “Gandalf” Smith, and the criminal charges he currently faces, have become a flashpoint in New Zealand’s medical cannabis debate. Proponents say the case illustrates tight advertising regulations and exorbitant prices that push patients to “green fairy” suppliers not subject to the law, Dec. 8, 2025.
Smith, 66 – who goes by the nickname “Gandalf the Green Fairy” — was arrested earlier this year after authorities raided his Far North property and ripped out dozens of plants and confiscated cannabis oils, court reports said. He pleaded not guilty to multiple charges of cultivation, possession for supply and supplying cannabis oil — crimes that can carry up to 14 years in prison when class B extracts are involved. The Guardian and local court coverage indicate.
More than 50 supporters, among them nurses and chronic pain patients, rallied outside Whangārei District Court calling for police to “free the green fairies” and describing the raid as political rather than being about safety. Green Party co-leader Chlöe Swarbrick says prosecuting an elderly supplier who provides cannabis to sick people is a “waste of public resources” that shows the divide between law and life for New Zealand medical users.
NZ medical cannabis scheme leaves patients in costly grey area.
The New Zealand medical cannabis scheme, which began in April 2020, allows patients to buy legal products only if prescribed by a doctor and the products meet quality standards established by the Medicinal Cannabis Agency. Officials say the scheme enhances access, but doctors continue to struggle with complex rules, and many products are not subsidised, meaning patients must pay full price.
Studies indicate the system continues to drive many patients underground. A 2025 Massey University survey showed prescriptions had increased, but about two-thirds of those using cannabis for health still obtained from illegal supply sources in part or completely, as legal products can cost hundreds of dollars a month. Clinics typically describe monthly spending for New Zealand medical cannabis as $100 to $400, more for high doses and imported oils.
Neither did the “Gandalf” argument come out of nowhere. So when he appeared in a 2019 television documentary by journalist Patrick Gower playing the role of “green fairy”, providing drugs to people excluded from the official system, this made sense: The same story was covered in a 2019 RNZ segment on cannabis and legalisation; a NZ Herald feature just this month cast him as a man bridging that compassionate gap at New Zealand’s medical cannabis policy. News27 May, 2016 “End of day for the green fairies?” 15 Dec, Earlier coverage of other green fairy prosecutions suggested police were already under pressure to apply the law on the ground, even though there was growing support for its medical applications.
Ad clampdown compounds fears as spotlight turns to New Zealand medical cannabis rules.
This year’s assault on Gandalf has coincided with new Medsafe advertising guidelines that severely restrict what clinics and suppliers can say about cannabis treatments. Rules issued in July 2025 treat most mentions of product names, THC or CBD content, cannabis leaf imagery, testimonials, or links to detailed information as “advertising,” effectively prohibiting them in public-facing materials and severely reducing what companies can inform prescribers about the treatments, according to industry outlet StratCann and official guidance.
Industry groups say the restrictions will further complicate doctors’ ability to understand their options and patients’ ability to provide informed consent, creating a barrier on top of already steep costs and patchy confidence in prescribing. Critics say that is exactly what has transpired: a New Zealand medical cannabis regime in which agencies warn clinics not to talk too loudly, even as police continue to arrest long-established community suppliers, who stepped into the breach while the legal market got up and running.
Officials defend both the enforcement action and the advertising clampdown as necessary to protect patients from unproven claims and dangerous products. Hundreds of new cannabis stores have opened, but adverts for the drug are still zoned out, legislation is waiting on the books and with Smith’s case winding its way through the courts, along with political divisions over what to do next on regulation post-referendum, campaigners say that their Gandalf raid will be a test case for whether policy swings in favour of harm reduction and affordability or whether New Zealand ends up with a labyrinthe accessible only by those who can afford it or are well-informed how to decode it.
